var data={"title":"Acetylcysteine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Acetylcysteine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5566?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=acetylcysteine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Acetylcysteine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=acetylcysteine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Acetylcysteine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130167\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Acetadote;</li>\n      <li>Cetylev</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130168\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Acetylcysteine Injection;</li>\n      <li>Acetylcysteine Solution;</li>\n      <li>Mucomyst;</li>\n      <li>Parvolex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130213\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote;</li>\n      <li>\n        Mucolytic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130171\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acetaminophen overdose:</b> Only the 72-hour oral and 21-hour IV regimens are FDA approved. Ideally, in patients with acute acetaminophen ingestion, treatment should begin within 8 hours of ingestion or as soon as possible after ingestion. In patients with a suspected acute ingestion where the time of ingestion is unknown, the concentration is unobtainable or uninterpretable within 8 hours of ingestion, the patient presents &gt;8 hours after ingestion, or there is clinical evidence of toxicity, initiate treatment immediately and re-evaluate the need for acetylcysteine upon receipt of the results (if applicable). In patients who present following RSTI and treatment is deemed appropriate, acetylcysteine should be initiated immediately. Regardless of the treatment regimen selected, serum acetaminophen concentrations, liver function, and clinical status should be evaluated during and prior to the end of the treatment regimen to determine if treatment discontinuation is appropriate. In patients who continue to experience symptoms of hepatotoxicity or elevated liver function tests at the conclusion of a 72-hour oral or 21-hour IV regimen, extending the treatment course may be appropriate; however, when and to which patients additional doses should be administered is unclear. Possible candidates for extended therapy include patients with a suspected massive overdose, concomitant ingestion of other substances, or patients with preexisting liver disease. In patients with persistently elevated acetaminophen concentrations, persistently elevated liver function tests, or an elevated INR, additional acetylcysteine should be administered. Typically, an additional &quot;third dose&quot; or &quot;third bag&quot; (IV: 100 mg/kg [maximum: 10 g] infused over 16 hours) is administered; however, this dose may be inadequate in some patients (Rumack 2012). Consultation with a poison control center or clinical toxicologist is highly recommended to determine optimal patient care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> (Effervescent tablets [Cetylev]; solution for oral administration): <b>Note:</b> Consultation with a poison control center or clinical toxicologist is highly recommended when considering the discontinuation of oral acetylcysteine prior to the conclusion of a full 18-dose course of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">72-hour regimen: Consists of 18 doses; total dose delivered: 1,330 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: 140 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: 70 mg/kg every 4 hours; repeat dose if emesis occurs within 1 hour of administration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV</i> (Acetadote):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">21-hour regimen: Consists of 3 doses; total dose delivered: 300 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: 150 mg/kg (maximum: 15 <b>g</b>) infused over 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Second dose: 50 mg/kg (maximum: 5 <b>g</b>) infused over 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Third dose: 100 mg/kg (maximum: 10 <b>g</b>) infused over 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> The fluid volume should be reduced in patients weighing &le;40 kg according to the following table:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Acetadote Dosing / Fluid Volume Guidelines for Patients &le;40 kg</caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Body Weight</p>\n            <p style=\"text-indent:0em;\">(kg)</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Loading Dose</p>\n            <p style=\"text-indent:0em;\">150 mg/kg over 1 hour</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Second Dose</p>\n            <p style=\"text-indent:0em;\">50 mg/kg over 4 hours</p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">Third Dose</p>\n            <p style=\"text-indent:0em;\">100 mg/kg over 16 hours</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Acetadote</p>\n            <p style=\"text-indent:0em;\">(mL)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Diluent</p>\n            <p style=\"text-indent:0em;\">(mL)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Acetadote</p>\n            <p style=\"text-indent:0em;\">(mL)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Diluent</p>\n            <p style=\"text-indent:0em;\">(mL)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Acetadote</p>\n            <p style=\"text-indent:0em;\">(mL)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Diluent</p>\n            <p style=\"text-indent:0em;\">(mL)</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">22.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">21</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15.75</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5.25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">250</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">500</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">140</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">280</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11.25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">45</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.75</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">105</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">210</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">7.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">70</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">140</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.75</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">15</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">35</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">70</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Obesity:</i> In patients who weigh &gt;100 kg, the following dosing regimen is recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Effervescent tablets (Cetylev): Limited information exists regarding the oral dosing requirements of patients &gt;100 kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">72-hour regimen: Consists of 18 doses; total dose delivered: 142.5 <b>g</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Loading dose: 15 <b>g</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maintenance dose: 7.5 <b>g</b> every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV (Acetadote): 21-hour regimen: Consists of 3 doses; total dose delivered: 30 <b>g</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 15 <b>g</b> infused over 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Second dose: 5 <b>g</b> infused over 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Third dose: 10 <b>g</b> infused over 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Adjuvant therapy in respiratory conditions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Patients should receive an aerosolized bronchodilator 10 to 15 minutes prior to dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inhalation, nebulization (face mask, mouth piece, tracheostomy):</i> Acetylcysteine 10% and 20% solution (dilute 20% solution with sodium chloride or sterile water for inhalation); 10% solution may be used undiluted: 3 to 5 mL of 20% solution or 6 to 10 mL of 10% solution until nebulized given 3 to 4 times/day; dosing range: 1 to 10 mL of 20% solution or 2 to 20 mL of 10% solution every 2 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inhalation, nebulization (tent, croupette):</i> Dose must be individualized; may require up to 300 mL solution/treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Direct instillation:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Into tracheostomy: 1 to 2 mL of 10% to 20% solution every 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Through percutaneous intratracheal catheter: 1 to 2 mL of 20% or 2 to 4 mL of 10% solution every 1 to 4 hours via syringe attached to catheter</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Diagnostic bronchogram:</b> Nebulization or intratracheal: 1 to 2 mL of 20% solution or 2 to 4 mL of 10% solution administered 2 to 3 times prior to procedure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130194\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=acetylcysteine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Acetylcysteine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acetaminophen overdose:</b> Infants, Children, and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Adjuvant therapy in respiratory conditions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Patients should receive an aerosolized bronchodilator 10 to 15 minutes prior to acetylcysteine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inhalation, nebulization (face mask, mouth piece, tracheostomy):</i> Acetylcysteine 10% and 20% solution (dilute 20% solution with sodium chloride or sterile water for inhalation); 10% solution may be used undiluted.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants: 1 to 2 mL of 20% solution or 2 to 4 mL 10% solution until nebulized given 3 to 4 times/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Inhalation, nebulization (tent, croupette):</i> Children: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130172\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671280\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Oral, IV: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671281\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Oral, IV: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20890195\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to indication-specific dosing for obesity-related information (may not be available for all indications). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130142\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, solution [preservative free]: 20% (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acetadote: 20% [200 mg/mL] (30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, for inhalation/oral: 10% [100 mg/mL] (10 mL, 30 mL); 20% [200 mg/mL] (10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, for inhalation/oral [preservative free]: 10% [100 mg/mL] (4 mL, 10 mL, 30 mL); 20% [200 mg/mL] (4 mL, 10 mL, 30 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Effervescent, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cetylev: 500 mg, 2.5 g [contains edetate disodium; lemon mint flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130127\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes; excludes effervescent tablet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130146\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalation: Acetylcysteine is incompatible with tetracyclines, erythromycin, amphotericin B, iodized oil, chymotrypsin, trypsin, and hydrogen peroxide. Administer separately. Intermittent aerosol treatments are commonly given when patient arises, before meals, and just before retiring at bedtime.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Effervescent tablets (Cetylev): Use within 2 hours of preparation. If the patient vomits within 1 hour of administration, repeat that dose. If the patient is persistently unable to retain the orally administered acetylcysteine, acetylcysteine may be administered by nasoduodenal tube. An intravenous formulation of acetylcysteine may also be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution for oral administration: For the treatment of acetaminophen overdose, administer orally as a 5% solution. Use within 1 hour of preparation. The unpleasant odor (sulfur-like) becomes less noticeable as treatment progresses. If patient vomits within 1 hour of dose, readminister. (<b>Note:</b> It is helpful to put the acetylcysteine on ice, in a cup with a cover, and drink through a straw; alternatively, administer via an NG tube).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV (Acetadote): Acetaminophen overdose:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Loading dose: Administer over 1 hour.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Second dose: Administer over 4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Third dose: Administer over 16 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If the commercial IV form is unavailable, the solution for inhalation has been used; each dose should be infused through a 0.2 micron Millipore filter (in-line) over 60 minutes (Yip 1998); intravenous administration of the solution for inhalation is not USP 797-compliant.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130145\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acetaminophen overdose:</b> To prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSTI).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mucolytic:</b> Adjunct therapy in patients with abnormal, viscid, or inspissated mucous secretions in conditions such as: chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis, primary amyloidosis of the lung); acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); pulmonary complications of cystic fibrosis; tracheostomy care; pulmonary complications associated with surgery; use during anesthesia; posttraumatic chest conditions; atelectasis due to mucous obstruction; diagnostic bronchial studies (bronchograms, bronchospirometry, bronchial wedge catheterization).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25720647\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Distal intestinal obstruction syndrome (DIOS, previously referred to as meconium ileus equivalent)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130222\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Acetylcysteine may be confused with acetylcholine </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mucomyst may be confused with Mucinex</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130134\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Intravenous:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&gt;10%: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Immunologic: Autoimmune disease (14% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Miscellaneous: Anaphylactoid reaction (1% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Cardiovascular: Flushing (1% to 3%), tachycardia (1% to 4%), edema (1% to 2%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Dermatologic: Urticaria (&le;21%), rash (2% to &le;21%), pruritus (1% to &le;21%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Gastrointestinal: Vomiting (2% to 10%), nausea (1% to 6%) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Respiratory: Pharyngitis (&le;1%), rhinorrhea (&le;1%), rhonchi (&le;1%), throat tightness (&le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports (limited to important or life-threatening): Anaphylaxis, angioedema, bronchospasm, chest tightness, cough, dizziness (Sandilands 2008), dyspnea (Sandilands 2008), hypotension, respiratory distress, stridor, wheezing </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Oral:</b> Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Chest tightness, hypotension (Bebarta 2010; Sandilands 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Rash (with or without fever), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Gastrointestinal symptoms, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Bronchospasm, bronchitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports (limited to important or life-threatening): Angioedema (Bebarta 2010), pruritus (Bebarta 2010), tachycardia (Bebarta 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130149\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to acetylcysteine or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Effervescent tablet (Cetylev): There are no contraindications listed in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130131\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid reactions: Acute flushing and erythema have been reported; usually occurs within 30 to 60 minutes and may resolve spontaneously. Serious anaphylactoid reactions (some fatal) have also been reported and are more commonly associated with IV administration, but also occur with oral administration (Mroz 1997). When used for acetaminophen overdose, the incidence is reduced when the initial intravenous loading dose is administered over 60 minutes. The acetylcysteine infusion may be interrupted until the treatment of allergic symptoms is initiated; the infusion can then be carefully restarted. Treatment for anaphylactoid reactions should be immediately available. Conversely, patients with high acetaminophen concentrations (&gt;150 mg/L) may be at a reduced risk for anaphylactoid reactions (Pakravan 2008; Sandilands 2009; Waring 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid overload: IV administration can cause fluid overload, potentially resulting in hyponatremia, seizure and death. To avoid fluid overload in patients &le;40 kg and those requiring fluid restriction, decrease volume of diluent proportionally (see table in dosing section).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma/bronchospasm: Use caution in patients with asthma or history of bronchospasm; these patients may be at increased risk of hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute acetaminophen overdose: Appropriate use: Acetylcysteine is indicated in patients with a serum acetaminophen concentration that indicates they are at &quot;possible&quot; risk or greater for hepatotoxicity when plotted on the Rumack-Matthew nomogram. There are several situations where the nomogram is of limited use. Serum acetaminophen concentrations obtained &lt;4 hours postingestion are not reliable, except to document the presence of acetaminophen (Seifert 2015). Patients presenting late may have undetectable serum concentrations, despite having received a toxic dose. The nomogram is less predictive of hepatic injury following an acute overdose with an extended release acetaminophen product. The nomogram also does not take into account patients who may be at higher risk of acetaminophen toxicity (eg, alcoholics, malnourished patients, concurrent use of CYP2E1 enzyme-inducing agents [eg, isoniazid]). Nevertheless, acetylcysteine should be administered to any patient with signs of hepatotoxicity, even if the serum acetaminophen concentration is low or undetectable. Patients who present &gt;24 hours after an acute ingestion or patients who present following an acute ingestion at an unknown time may be candidates for acetylcysteine therapy; consultation with a poison control center or clinical toxicologist is highly recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Repeated supratherapeutic ingestion (RSTI) of acetaminophen: Appropriate use: The Rumack-Matthew nomogram is not designed to be used following RSTIs. In general, an accurate past medical history, including a comprehensive acetaminophen ingestion history, in conjunction with AST concentrations and serum acetaminophen concentrations, may give the clinician insight as to the patient's risk of acetaminophen toxicity. Some experts recommend that acetylcysteine be administered to any patient with &quot;higher than expected&quot; serum acetaminophen concentrations or serum acetaminophen concentration &gt;10 mcg/mL, even in the absence of hepatic injury; others recommend treatment for patients with laboratory evidence and/or signs and symptoms of hepatotoxicity (Hendrickson 2006; Jones 2000). Consultation with a poison control center or a clinical toxicologist is highly recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effervescent tablets (Cetylev): Contains sodium; consider acetylcysteine treatment as a source of sodium in patients who may be sensitive to excess sodium intake (eg, heart failure, hypertension, renal impairment).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral administration: Gastrointestinal hemorrhage: Oral administration of acetylcysteine may result in nausea and vomiting, which may exacerbate vomiting associated with acetaminophen overdose. Therefore, patients at risk of gastrointestinal hemorrhage (eg, esophageal varices, peptic ulcer) may experience an even higher risk of gastrointestinal hemorrhage during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inhalation: Since increased bronchial secretions may develop after inhalation, percussion, postural drainage, and suctioning should follow. If bronchospasm occurs, administer a bronchodilator; discontinue acetylcysteine if bronchospasm progresses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298677\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130136\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9317&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130152\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Based on limited reports using acetylcysteine to treat acetaminophen overdose in pregnant women, acetylcysteine has been shown to cross the placenta and may provide protective concentrations in the fetus.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Acetylcysteine may be used to treat acetaminophen overdose in during pregnancy (Wilkes 2005). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20517978\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if acetylcysteine is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother. Based on pharmacokinetics, acetylcysteine should be nearly completely cleared 30 hours after administration; breast-feeding women may consider pumping and discarding breast milk for 30 hours after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130140\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen overdose: Monitor patient for the development of anaphylaxis or anaphylactoid reactions; monitor serum acetaminophen concentrations, AST, ALT, bilirubin, PT, INR, serum creatinine, BUN, serum glucose, hemoglobin, hematocrit, and electrolytes. Assess patient for nausea, vomiting, and skin rash following oral administration. Reassess LFTs for possible hepatotoxicity every 4 to 6 hours. An early elevation in the INR may be related to acetylcysteine therapy (Schmidt 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acute ingestion: Obtain the first acetaminophen concentration 4 hours postingestion (or as soon as possible thereafter); plot on the Rumack-Matthew nomogram. In patients who have ingested an extended release formulation of acetaminophen or have coingested an agent known to delay gastric emptying, obtain a repeat serum acetaminophen measurement 4 to 6 hours following the first measurement if the original concentration (taken at 4 to 8 hours postingestion) when plotted on the Rumack-Matthew nomogram indicated that treatment was not necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130130\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen overdose: Acetylcysteine acts as a hepatoprotective agent by restoring hepatic glutathione, serving as a glutathione substitute, and enhancing the nontoxic sulfate conjugation of acetaminophen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mucolytic: Exerts mucolytic action through its free sulfhydryl group which opens up the disulfide bonds in the mucoproteins thus lowering mucous viscosity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130148\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Inhalation: 5 to 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Inhalation: &gt;1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 0.47 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 66% to 87%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Undergoes extensive first pass metabolism to form cysteine and disulfides (N,N-diacetylcysteine and N-acetylcysteine); cysteine is further metabolized to form glutathione and other metabolites</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Reduced acetylcysteine: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Total acetylcysteine: Adults: 5.6 hours; Newborns: 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Effervescent tablets: Terminal half-life: 18.1 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Oral solution: 1 to 2 hours; Effervescent tablets: 1 to 3.5 hours (median: 2 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (13% to 38%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130151\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Acetadote Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (30 mL): $258.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Acetylcysteine Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10% (10 mL): $12.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20% (10 mL): $14.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Acetylcysteine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/mL (30 mL): $225.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, effervescent</b> (Cetylev Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 g (20): $433.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (20): $86.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F130153\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ac-Lyte (PH);</li>\n      <li>ACC (AR, BG, CH, CR, CZ, DE, DO, GT, HN, HU, LB, LU, MX, NI, PA, RU, SA, SK, SV, ZA);</li>\n      <li>ACC 200 (AE, BH, EE, KW, QA);</li>\n      <li>ACC Long (QA);</li>\n      <li>Acemuc (EC);</li>\n      <li>Acemuk (AR, CL);</li>\n      <li>Acet (TW);</li>\n      <li>Acetadote (AU, NZ);</li>\n      <li>Acetein (KR);</li>\n      <li>Acetimax (PH);</li>\n      <li>Acetin (ID, MY);</li>\n      <li>Acetylcystein NM Pharma (SE);</li>\n      <li>Acetylcystein Tika (SE);</li>\n      <li>Acetyst (DE);</li>\n      <li>Actein (HK);</li>\n      <li>Aflux (CO, EC);</li>\n      <li>Aires (BR);</li>\n      <li>Bisolbruis (NL);</li>\n      <li>Brimodin (PE);</li>\n      <li>Bromuc (BR);</li>\n      <li>Bronchocil (BE);</li>\n      <li>Broncoflem (PH);</li>\n      <li>Broncolium (AR);</li>\n      <li>Brunac (JO);</li>\n      <li>Cetilan (PH);</li>\n      <li>Cilol (LK);</li>\n      <li>Cirocyst (LK);</li>\n      <li>Codotussyl (SG);</li>\n      <li>Cystaline (TH);</li>\n      <li>Dextein (PH);</li>\n      <li>Drenaflen (DO, EC);</li>\n      <li>Ecomucyl (CH);</li>\n      <li>Encore (TW);</li>\n      <li>Enumine NAC (TH);</li>\n      <li>Exflem (PH);</li>\n      <li>Exomuc (FR, LB, LU, VN);</li>\n      <li>Fabrol (AT, GR);</li>\n      <li>Flemex AC (TH);</li>\n      <li>Flemex-AC OD (TH);</li>\n      <li>Flucil (TH);</li>\n      <li>Fluidasa (CL, VN);</li>\n      <li>Fluidine (EC);</li>\n      <li>Fluimicil (CH, DE);</li>\n      <li>Fluimiquil (LU);</li>\n      <li>Fluimucil (AR, AT, BG, BR, CO, CZ, ES, FR, GR, HK, HU, ID, IT, LB, NL, PE, PL, PT, QA, RU, SA, SG, TH, TW, VN);</li>\n      <li>Fluimucil A (MY, PK);</li>\n      <li>Fluimukan (HR, SI);</li>\n      <li>Flumex (PH);</li>\n      <li>Flumil (ES);</li>\n      <li>Flumixol (CO);</li>\n      <li>Flutafin (TW);</li>\n      <li>Genac (FR);</li>\n      <li>Glotamuc (VN);</li>\n      <li>Granon (DK);</li>\n      <li>Hidonac (HK, ID, MY, PH, TH, TW);</li>\n      <li>Icystein (TW);</li>\n      <li>Ilube (GB);</li>\n      <li>L-Cimexyl (SG);</li>\n      <li>Lubrisec (AR);</li>\n      <li>Lysomucil (BE, CR, DO, GT, HN, LU, NI, PA, SV);</li>\n      <li>Lysox (BE, LU);</li>\n      <li>Madame Pearl's Mucolytic (HK);</li>\n      <li>Mentopin (MY, SG);</li>\n      <li>Mitux (VN);</li>\n      <li>Moktin (KR);</li>\n      <li>Muclear (TH);</li>\n      <li>Mucobene (AT);</li>\n      <li>Mucocar (PE);</li>\n      <li>Mucocystein (PH);</li>\n      <li>Mucofillin (JP);</li>\n      <li>Mucofluid (EE);</li>\n      <li>Mucolair (LU);</li>\n      <li>Mucolator (LU, MY);</li>\n      <li>Mucolitico (CL, CN);</li>\n      <li>Mucolysin (IS);</li>\n      <li>Mucolyte (LK);</li>\n      <li>Mucomist (BD);</li>\n      <li>Mucomyst (DK, FI, FR, GR, KR, LU, NO, SE);</li>\n      <li>Mucomystendo (FR);</li>\n      <li>Mucoserin (KR);</li>\n      <li>Mucosoft (BG);</li>\n      <li>Mucosten (KR);</li>\n      <li>Mucosys (IN);</li>\n      <li>Mucylin (ID);</li>\n      <li>Mufresin (PH);</li>\n      <li>Muterin (KR);</li>\n      <li>Muxatil (PY);</li>\n      <li>Mysoven (TH);</li>\n      <li>N-Acc (ID);</li>\n      <li>NAC (TR);</li>\n      <li>NAC-ratiopharm (LU);</li>\n      <li>Nacetyl (PH);</li>\n      <li>Parvolex (GB, IE, NZ, ZA);</li>\n      <li>Pectocil (ID);</li>\n      <li>Pectomucil (LU);</li>\n      <li>Pulmovital (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Reolin (IL);</li>\n      <li>Respar (ID);</li>\n      <li>Rinofluimucil (JO);</li>\n      <li>Rumicil (LU);</li>\n      <li>Sebron (KR);</li>\n      <li>Sensemoc (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Simucil (ID);</li>\n      <li>Simucin (TH);</li>\n      <li>Siran 200 (IL);</li>\n      <li>Siran Forte (ID);</li>\n      <li>Solmucol (CZ, HU, IT, LU, SG, SK);</li>\n      <li>Spatam (SG);</li>\n      <li>Sputopur (HU);</li>\n      <li>Stacytine (VN);</li>\n      <li>Stecin (KR);</li>\n      <li>Stenac (MY);</li>\n      <li>Systalin (BD);</li>\n      <li>Tancore (TW);</li>\n      <li>Tirocular (PT);</li>\n      <li>Toflux (AR);</li>\n      <li>Touxium Mucolyticum (LU);</li>\n      <li>Viscotin (BD);</li>\n      <li>Viskoferm (SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Acetadote (acetylcysteine) [prescribing information]. Nashville, TN: Cumberland Pharmaceuticals Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Acetylcysteine injection [prescribing information]. Lake Forest, IL: Akorn, Inc; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACT Investigators, &ldquo;Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results from the Randomized Acetylcysteine for Contrast-induced Nephropathy Trial (ACT),&rdquo; <i>Circulation</i>, 2011, 124(11):1250-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/21859972/pubmed\" target=\"_blank\" id=\"21859972\">21859972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2014;130(25):e433-e434]. <i>Circulation</i>. 2014;130(25):e344-e426.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/25249585/pubmed\" target=\"_blank\" id=\"25249585\">25249585</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Appelboam AV, Dargan PI, and Knighton J, &ldquo;Fatal Anaphylactoid Reaction to N-Acetylcysteine: Caution in Patients With Asthma,&rdquo; <i>Emerg Med J</i>, 2002, 19(6):594-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/12421803/pubmed\" target=\"_blank\" id=\"12421803\">12421803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B and McGuigan MA, &ldquo;Management of Anaphylactoid Reactions to Intravenous N-Acetylcysteine,&rdquo; <i>Ann Emerg Med</i>, 1998, 31(6):710-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/9624310/pubmed\" target=\"_blank\" id=\"9624310\">9624310</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baker CS, Wragg A, Kumar S, et al, &quot;A Rapid Protocol for the Prevention of Contrast-Induced Renal Dysfunction: The RAPPID Study,&rdquo; <i>J Am Coll Cardiol</i>, 2003, 41(12):2114-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/12821233/pubmed\" target=\"_blank\" id=\"12821233\">12821233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bebarta VS, Kao L, Froberg B, et al, &quot;A Multicenter Comparison of the Safety of Oral Versus Intravenous Acetylcysteine for Treatment of Acetaminophen Overdose,&quot; <i>Clin Toxicol (Phila)</i>, 2010, 48(5):424-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/20524832/pubmed\" target=\"_blank\" id=\"20524832\">20524832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Briguori C, Airoldi F, D&rsquo;Andrea D, et al, &ldquo;Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL). A Randomized Comparison of 3 Preventive Strategies,&rdquo; <i>Circulation</i>, 2007, 115(10):1211-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/17309916/pubmed\" target=\"_blank\" id=\"17309916\">17309916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cetylev (acetylcysteine) [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dart RC, Erdman AR, Olson KR, et al, &ldquo;Acetaminophen Poisoning: An Evidence-Based Consensus Guideline for Out-of-Hospital Management,&rdquo; <i>Clin Toxicol (Phila)</i>, 2006, 44(1):1-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/16496488/pubmed\" target=\"_blank\" id=\"16496488\">16496488</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Douglas D and Smilkstein M, &ldquo;Deferoxamine-Iron Induced Pulmonary Injury and N-Acetylcysteine,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1995, 33(5):495.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Falk JL, &ldquo;Oral N-Acetylcysteine Given Intravenously for Acetaminophen Overdose: We Shouldn't Have To, But We Must,&rdquo; <i>Crit Care Med</i>, 1998, 26(1):7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/9428532/pubmed\" target=\"_blank\" id=\"9428532\">9428532</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harrison PM, Keays R, Bray BP, et al, &ldquo;Improved Outcome of Paracetamol-Induced Fulminant Hepatic Failure by Late Administration of Acetylcysteine,&rdquo; <i>Lancet</i>, 1990, 335(8705):1572-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/1972496/pubmed\" target=\"_blank\" id=\"1972496\">1972496</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hendrickson RG and Bizovi KE, &ldquo;Acetaminophen,&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 8th edition, Flomenbaum NE, Goldfrank LR, Hoffman RS, et al, eds, New York: The McGraw-Hill Companies, Inc, 2006, 523-43.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones AL, &ldquo;Mechanism of Action and Value of N-Acetylcysteine in the Treatment of Early and Late Acetaminophen Poisoning: A Critical Review,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1998, 36(4):277-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/9711192/pubmed\" target=\"_blank\" id=\"9711192\">9711192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones AL, &ldquo;Recent Advances in the Management of Late Paracetamol Poisoning,&rdquo; <i>Emerg Med</i>, 2000, 12(1):14-21.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kay J, Chow WH, Chan TM, et al, &ldquo;Acetylcysteine for Prevention of Acute Deterioration of Renal Function Following Elective Coronary Angiography and Intervention: A Randomized Controlled Trial,&rdquo; <i>JAMA</i>, 2003, 289(5):553-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/12578487/pubmed\" target=\"_blank\" id=\"12578487\">12578487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keays R, Harrison PM, Wendon JA, et al, &ldquo;Intravenous Acetylcysteine in Paracetamol Induced Fulminant Hepatic Failure: A Prospective Controlled Trial,&rdquo; <i>BMJ</i>, 1991, 303(6809):1026-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/1954453/pubmed\" target=\"_blank\" id=\"1954453\">1954453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(suppl 1):1-138. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO%20AKI%20Guideline.pdf. Published March 2012. Accessed January 9, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mascarenhas MR, &ldquo;Treatment of Gastrointestinal Problems in Cystic Fibrosis,&rdquo; <i>Curr Treat Options Gastroenterol</i>, 2003, 6(5):427-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/12954149/pubmed\" target=\"_blank\" id=\"12954149\">12954149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mohammed S, Jamal AZ, and Robison LR, &ldquo;Serum Sickness-Like Illness Associated With N-Acetylcysteine Therapy,&rdquo; <i>Ann Pharmacother</i>, 1994, 28(2):285.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/8173157/pubmed\" target=\"_blank\" id=\"8173157\">8173157</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo; <i>Chest</i>, 2003, 123(3):897-922.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/12628894/pubmed\" target=\"_blank\" id=\"12628894\">12628894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mroz L, Benitez JG, and Krenzelok E, &ldquo;Angioedema With Oral Acetylcysteine,&rdquo; <i>Ann Emerg Med</i>, 1997, 30(2):240-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/9250658/pubmed\" target=\"_blank\" id=\"9250658\">9250658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pakravan N, Waring WS, Sharma S, et al, &ldquo;Risk Factors and Mechanisms of Anaphylactoid Reactions to Acetylcysteine in Acetaminophen Overdose,&rdquo; <i>Clin Toxicol</i>, 2008, 46(8):697-702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/18803085/pubmed\" target=\"_blank\" id=\"18803085\">18803085</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prescott LF, Donovan JW, Jarvie DR, et al, &ldquo;The Disposition and Kinetics of Intravenous N-Acetylcysteine in Patients With Paracetamol Overdosage,&rdquo; <i>Eur J Clin Pharmacol</i>, 1989, 37(5):501-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/2598989/pubmed\" target=\"_blank\" id=\"2598989\">2598989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prescott LF, Illingworth RN, Critchley JA, et al, &ldquo;Intravenous N-Acetylcysteine: The Treatment of Choice for Paracetamol Poisoning,&rdquo; <i>BMJ</i>, 1979, 2:1097-1100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/519312/pubmed\" target=\"_blank\" id=\"519312\">519312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodgers G, Matyunas N, Ross M, et al, &ldquo;Sulfhemoglobinemia Associated With N-Acetylcysteine (NAC) Therapy of Acetaminophen (APAP) Overdose: A Case Report,&rdquo; <i>Clin Toxicol</i>, 1995, 33(5):530.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rumack BH and Bateman DN, &quot;Acetaminophen and Acetylcysteine Dose and Duration: Past, Present and Future,&quot; <i>Clin Toxicol (Phila)</i>, 2012, 50(2):91-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/22320209/pubmed\" target=\"_blank\" id=\"22320209\">22320209</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandilands EA and Bateman DN, &ldquo;Adverse Reactions Associated With Acetylcysteine,&rdquo; <i>Clin Toxicol (Phila)</i>, 2009, 47(2):81-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/19280424/pubmed\" target=\"_blank\" id=\"19280424\">19280424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt LE, Knudsen TT, Dalhoff K, et al, &ldquo;Effect of Acetylcysteine on Prothrombin Index in Paracetamol Poisoning Without Hepatocellular Injury,&rdquo; <i>Lancet</i>, 2002, 360(9340):1151-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/12387966/pubmed\" target=\"_blank\" id=\"12387966\">12387966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seifert SA, Kirschner RI, Martin TG, Schrader RM, Karowski K, Anaradian PC. Acetaminophen concentrations prior to 4 hours of ingestion: impact on diagnostic decision-making and treatment. <i>Clin Toxicol</i>. 2015;53(7):618-623.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/26107627/pubmed\" target=\"_blank\" id=\"26107627\">26107627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smilkstein MJ, Bronstein AC, Linden C, &ldquo;Acetaminophen Overdose: A 48-Hour Intravenous N-Acetylcysteine Treatment Protocol,&quot; <i>Ann Emerg Med</i>, 1991, 20(10):1058-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/1928874/pubmed\" target=\"_blank\" id=\"1928874\">1928874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smilkstein MJ, Knapp GL, Kulig KW, et al, &ldquo;Efficacy of N-Acetylcysteine in the Treatment of Acetaminophen Overdose: Analysis of the National Multicenter Study (1976 to 1985),&rdquo; <i>N Engl J Med</i>, 1988, 319(24):1557-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/3059186/pubmed\" target=\"_blank\" id=\"3059186\">3059186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Subramaniam RM, Suarez-Cuervo C, Wilson RF, et al. Effectiveness of prevention strategies for contrast-induced nephropathy: a systematic review and meta-analysis. <i>Ann Intern Med</i>. 2016;164(6):406-416. doi: 10.7326/M15-1456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/26830221/pubmed\" target=\"_blank\" id=\"26830221\">26830221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Szabo E, Mao JT, Lam S, Reid ME, Keith RL. Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest.</i> 2013;143(5 Suppl):e40S-60S.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/23649449/pubmed\" target=\"_blank\" id=\"23649449\">23649449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tepel M, van der Giet M, Schwarzfeld C, et al, &ldquo;Prevention of Radiographic-Contrast-Agent-Induced Reductions in Renal Function by Acetylcysteine,&rdquo; <i>N Engl J Med</i>, 2000, 343(3):180-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/10900277/pubmed\" target=\"_blank\" id=\"10900277\">10900277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walson PD and Groth JF Jr, &ldquo;Acetaminophen Hepatotoxicity After Prolonged Ingestion,&rdquo; <i>Pediatrics</i>, 1993, 91(5):1021-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/8474802/pubmed\" target=\"_blank\" id=\"8474802\">8474802</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waring WS, Stephen AF, Robinson OD, et al,&ldquo;Lower Incidence of Anaphylactoid Reactions to N-Acetylcysteine in Patients With High Acetaminophen Concentrations After Overdose,&rdquo; <i>Clin Toxicol (Phila)</i>, 2008, 46(6):496-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/18584360/pubmed\" target=\"_blank\" id=\"18584360\">18584360</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weisbord SD, Gallagher M, Jneid H, et al; PRESERVE Trial Group. Outcomes after angiograph with sodium bicarbonate and acetylcysteine. <i>N Engl J Med.</i> 2017. doi: 10.1056/NEJMoa1710933.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/29130810/pubmed\" target=\"_blank\" id=\"29130810\">29130810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilkes JM, Clark LE, and Herrera JL, &quot;Acetaminophen Overdose in Pregnancy,&quot; <i>South Med J</i>, 2005, 98(11):1118-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/16351032/pubmed\" target=\"_blank\" id=\"16351032\">16351032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>Eur Heart J</i>. 2014;35(37):2541-2619. doi: 10.1093/eurheartj/ehu278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/25173339/pubmed\" target=\"_blank\" id=\"25173339\">25173339</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Woo OF, Anderson IB, Kim SY, et al, &ldquo;Shorter Duration of N-Acetylcysteine (NAC) for Acute Acetaminophen Poisoning,&rdquo; <i>Clin Toxicol</i>, 1995, 33(5):508.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Woo OF, Mueller PD, Olson KR, et al, &ldquo;Shorter Duration of Oral N-Acetylcysteine Therapy for Acute Acetaminophen Overdose,&rdquo; <i>Ann Emerg Med</i>, 2000, 35(4):363-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/10736123/pubmed\" target=\"_blank\" id=\"10736123\">10736123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yankaskas JR, Marshall BC, Sufian B, et al, &ldquo;Cystic Fibrosis Adult Care: Consensus Conference Report,&rdquo; <i>Chest</i>, 2004, 125(1 Suppl):1-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/14734689/pubmed\" target=\"_blank\" id=\"14734689\">14734689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yip L, Dart RC, and Hurlbut KM, &ldquo;Intravenous Administration of Oral N-Acetylcysteine,&rdquo; <i>Crit Care Med</i>, 1998, 26(1):40-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/9428541/pubmed\" target=\"_blank\" id=\"9428541\">9428541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zyoud SH, Awang R, Sulaiman SA, et al, &ldquo;Incidence of Adverse Drug Reactions Induced by N-Acetylcysteine in Patients With Acetaminophen Overdose,&rdquo; <i>Hum Exp Toxicol</i>, 2010, 29(3):153-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/20071472/pubmed\" target=\"_blank\" id=\"20071472\">20071472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zyoud SH, Awang R, Sulaiman SA, et al, &ldquo;N-Acetylcysteine-Induced Headache in Hospitalized Patients With Acute Acetaminophen Overdose,&rdquo; <i>Fundam Clin Pharmacol</i>, 2011, 25(3):405-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/acetylcysteine-drug-information/abstract-text/20584210/pubmed\" target=\"_blank\" id=\"20584210\">20584210</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9317 Version 143.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F130167\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F130168\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F130213\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F130171\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F130194\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F130172\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15671280\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15671281\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20890195\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F130142\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F130127\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F130146\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F130145\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25720647\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F130222\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F130134\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F130149\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F130131\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298677\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F130136\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F130152\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20517978\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F130140\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F130130\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F130148\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F130151\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F130153\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9317|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=acetylcysteine-patient-drug-information\" class=\"drug drug_patient\">Acetylcysteine: Patient drug information</a></li><li><a href=\"topic.htm?path=acetylcysteine-pediatric-drug-information\" class=\"drug drug_pediatric\">Acetylcysteine: Pediatric drug information</a></li></ul></div></div>","javascript":null}